Search

Your search keyword '"van der Veldt, Astrid A. M."' showing total 502 results
Start Over Author "van der Veldt, Astrid A. M."
502 results on '"van der Veldt, Astrid A. M."'

102. Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands

Author

van Breeschoten, Jesper, primary, van den Eertwegh, Alfonsus J. M., additional, de Wreede, Liesbeth C., additional, Hilarius, Doranne L., additional, van Zwet, Erik W., additional, Haanen, John B., additional, Blank, Christian U., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, de Groot, Jan Willem B., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen, additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Stevense-den Boer, Marion A. M., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Boers-Sonderen, Marye J., additional, Suijkerbuijk, Karijn P. M., additional, and Wouters, Michel W. J. M., additional

Published
2021
Full Text
View/download PDF

104. Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

Author

de Glas, Nienke A., primary, Bastiaannet, Esther, additional, van den Bos, Frederiek, additional, Mooijaart, Simon P., additional, van der Veldt, Astrid A. M., additional, Suijkerbuijk, Karlijn P. M., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan-Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Jalving, Hilde, additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, ten Tije, Albert J., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Portielje, Johanneke E. A., additional, and Kapiteijn, Ellen W., additional

Published
2021
Full Text
View/download PDF

105. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Author

Ismail, Rawa K, Sikkes, Nienke O, Wouters, Michel W J M, Hilarius, Doranne L, Pasmooij, Anna M G, van den Eertwegh, Alfonsus J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Ten Tije, Bert-Jan, van der Veldt, Astrid A M, Vreugdenhil, Art, van Dartel, Maaike, de Boer, Anthonius, Ismail, Rawa K, Sikkes, Nienke O, Wouters, Michel W J M, Hilarius, Doranne L, Pasmooij, Anna M G, van den Eertwegh, Alfonsus J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Ten Tije, Bert-Jan, van der Veldt, Astrid A M, Vreugdenhil, Art, van Dartel, Maaike, and de Boer, Anthonius

Abstract

Postapproval trials and patient registries have their pros and cons in the generation of postapproval data. No direct comparison between clinical outcomes of these data sources currently exists for advanced melanoma patients. We aimed to investigate whether a patient registry can complement or even replace postapproval trials. Postapproval single-arm clinical trial data from the Medicines Evaluation Board and real-world data from the Dutch Melanoma Treatment Registry were used. The study population consisted of advanced melanoma patients with brain metastases treated with targeted therapies (BRAF- or BRAF-MEK inhibitors) in the first line. A Cox hazard regression model and a propensity score matching (PSM) model were used to compare the two patient populations. Compared to patients treated in postapproval trials (n = 467), real-world patients (n = 602) had significantly higher age, higher ECOG performance status, more often ≥3 organ involvement and more symptomatic brain metastases. Lactate dehydrogenase levels were similar between both groups. The unadjusted median overall survival (mOS) in postapproval clinical trial patients was 8.7 (95% CI, 8.1-10.4) months compared to 7.2 (95% CI, 6.5-7.7) months (P < 0.01) in real-world patients. With the Cox hazard regression model, survival was adjusted for prognostic factors, which led to a statistically insignificant difference in mOS for trial and real-world patients of 8.7 (95% CI, 7.9-10.4) months compared to 7.3 (95% CI, 6.3-7.9) months, respectively. The PSM model resulted in 310 matched patients with similar survival (P = 0.9). Clinical outcomes of both data sources were similar. Registries could be a complementary data source to postapproval clinical trials to establish information on clinical outcomes in specific subpopulations.

Published
2021

106. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Ismail, Rawa K, Sikkes, Nienke O, Wouters, Michel W J M, Hilarius, Doranne L, Pasmooij, Anna M G, van den Eertwegh, Alfonsus J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Ten Tije, Bert-Jan, van der Veldt, Astrid A M, Vreugdenhil, Art, van Dartel, Maaike, de Boer, Anthonius, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Ismail, Rawa K, Sikkes, Nienke O, Wouters, Michel W J M, Hilarius, Doranne L, Pasmooij, Anna M G, van den Eertwegh, Alfonsus J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Ten Tije, Bert-Jan, van der Veldt, Astrid A M, Vreugdenhil, Art, van Dartel, Maaike, and de Boer, Anthonius

Published
2021

107. Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

Author

de Glas, Nienke A, Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P, van der Veldt, Astrid A M, Suijkerbuijk, Karlijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan-Willem B, Haanen, John B A G, Hospers, Geke A P, Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W J M, Portielje, Johanneke E A, Kapiteijn, Ellen W, de Glas, Nienke A, Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P, van der Veldt, Astrid A M, Suijkerbuijk, Karlijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Groot, Jan-Willem B, Haanen, John B A G, Hospers, Geke A P, Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, Vreugdenhil, Gerard, Wouters, Michel W J M, Portielje, Johanneke E A, and Kapiteijn, Ellen W

Abstract

BACKGROUND: Previous trials suggest no differences in immunotherapy treatment between older and younger patients, but mainly young patients with a good performance status were included. The aim of this study was to describe the treatment patterns and outcomes of "real-world" older patients with metastatic melanoma and to identify predictors of outcome.METHODS: We included patients aged ≥65 years with metastatic melanoma from the Dutch Melanoma Treatment Registry. We described the reasons for hospital admissions and treatment discontinuation. Additionally, we assessed predictors of toxicity and response using logistic regression models and survival using Cox regression models.RESULTS: We included 2216 patients. Grade ≥3 toxicity was not associated with age, comorbidities or WHO status. Patients aged ≥75 discontinued treatment due to toxicity more often, resulting in fewer treatment cycles. Response rates were similar to previous trials (40.3% and 43.6% in patients aged 65-75 and ≥75, respectively, for anti-PD1 treatment) and did not decrease with age or comorbidity. Melanoma-specific survival was not affected by age or comorbidity.CONCLUSION: Response rates and toxicity outcomes of checkpoint inhibitors did not change with increasing age or comorbidity. However, the impact of grade I-II toxicity on quality of life deserves further study as older patients discontinue treatment more frequently.

Published
2021

108. Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma:A Nationwide Cohort Study

Author

van der Kooij, Monique K, Dekkers, Olaf M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Westgeest, Hans M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wilgenhof, Sofie, Wouters, Michel W J M, Haanen, John B A G, van den Eertwegh, Alfonsus J M, Kapiteijn, Ellen, van der Kooij, Monique K, Dekkers, Olaf M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Westgeest, Hans M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wilgenhof, Sofie, Wouters, Michel W J M, Haanen, John B A G, van den Eertwegh, Alfonsus J M, and Kapiteijn, Ellen

Abstract

Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013-July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3-4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients ≥60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference.

Published
2021

109. An Overview of Liver Directed Locoregional Therapies

Author

Höppener, Diederik J, Grünhagen, Dirk J, Eggermont, Alexander M M, van der Veldt, Astrid A M, Verhoef, Cornelis, Höppener, Diederik J, Grünhagen, Dirk J, Eggermont, Alexander M M, van der Veldt, Astrid A M, and Verhoef, Cornelis

Abstract

An overview of all liver-directed locoregional therapies, including surgical resection for melanoma liver metastases (MLMs), is provided. MLM patients are divided by their primary melanoma location; cutaneous, uvea (eye), and mucosal melanoma. If patients with isolated cutaneous MLMs are considered for surgical resection, treatment with systemic therapy should be part of the treatment course. For uveal MLMs, complete surgical or ablative treatment of all MLMs suggests superior results compared with other liver-directed or systemic therapies, based on current evidence, no recommendations for any liver-directed regional therapy in the treatment of mucosal MLMs can be made.

Published
2021

110. Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study

Author

MS Medische Oncologie, Infection & Immunity, Cancer, van der Kooij, Monique K, Dekkers, Olaf M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Westgeest, Hans M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wilgenhof, Sofie, Wouters, Michel W J M, Haanen, John B A G, van den Eertwegh, Alfonsus J M, Kapiteijn, Ellen, MS Medische Oncologie, Infection & Immunity, Cancer, van der Kooij, Monique K, Dekkers, Olaf M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, de Groot, Jan Willem B, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Westgeest, Hans M, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wilgenhof, Sofie, Wouters, Michel W J M, Haanen, John B A G, van den Eertwegh, Alfonsus J M, and Kapiteijn, Ellen

Published
2021

111. Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Jochems, Anouk, Bastiaannet, Esther, Aarts, Maureen J B, van Akkooi, Alexander C J, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Glas, Nienke G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, van der Hoeven, Jacobus J M, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Kapiteijn, Ellen, Wouters, Michel W J M, MS Medische Oncologie, Infection & Immunity, Cancer, Jochems, Anouk, Bastiaannet, Esther, Aarts, Maureen J B, van Akkooi, Alexander C J, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, de Glas, Nienke G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, van der Hoeven, Jacobus J M, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Kapiteijn, Ellen, and Wouters, Michel W J M

Published
2021

112. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Ten Tije, Bert-Jan J, van der Veldt, Astrid A M, Vreugdenhil, Art, Boers-Sonderen, Marye J, van den Eertwegh, Alfonsus J M, MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, Hilarius, Doranne L, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Ten Tije, Bert-Jan J, van der Veldt, Astrid A M, Vreugdenhil, Art, Boers-Sonderen, Marye J, and van den Eertwegh, Alfonsus J M

Published
2021

113. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Biewenga, Maaike, van der Kooij, Monique K, Wouters, Michel W J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Boers-Sonderen, Marye J, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Haanen, John B A G, van der Eertwegh, Alfons J M, van Hoek, Bart, Kapiteijn, Ellen, MS Medische Oncologie, Infection & Immunity, Cancer, Biewenga, Maaike, van der Kooij, Monique K, Wouters, Michel W J M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Boers-Sonderen, Marye J, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Haanen, John B A G, van der Eertwegh, Alfons J M, van Hoek, Bart, and Kapiteijn, Ellen

Published
2021

114. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Versluis, Judith M, Hendriks, Anne M, Weppler, Alison M, Brown, Lauren J, de Joode, Karlijn, Suijkerbuijk, Karijn P M, Zimmer, Lisa, Kapiteijn, Ellen W, Allayous, Clara, Johnson, Douglas B, Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J L, Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A, Neyns, Bart, Haydon, Andrew, Menzies, Alexander M, Long, Georgina V, Lebbe, Celeste, van der Veldt, Astrid A M, Carlino, Matteo S, Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G E, Blank, Christian U, Jalving, Mathilde, MS Medische Oncologie, Infection & Immunity, Cancer, Versluis, Judith M, Hendriks, Anne M, Weppler, Alison M, Brown, Lauren J, de Joode, Karlijn, Suijkerbuijk, Karijn P M, Zimmer, Lisa, Kapiteijn, Ellen W, Allayous, Clara, Johnson, Douglas B, Hepner, Adriana, Mangana, Joanna, Bhave, Prachi, Jansen, Yanina J L, Trojaniello, Claudia, Atkinson, Victoria, Storey, Lucy, Lorigan, Paul, Ascierto, Paolo A, Neyns, Bart, Haydon, Andrew, Menzies, Alexander M, Long, Georgina V, Lebbe, Celeste, van der Veldt, Astrid A M, Carlino, Matteo S, Sandhu, Shahneen, van Tinteren, Harm, de Vries, Elisabeth G E, Blank, Christian U, and Jalving, Mathilde

Published
2021

115. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Verver, Danielle, Grünhagen, Dirk J, van Akkooi, Alexander C J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Boers-Sonderen, Marye J, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Tije, Albert J Ten, Vreugdenhil, Gerard, Verhoef, Cornelis, van der Veldt, Astrid A M, MS Medische Oncologie, Infection & Immunity, Cancer, Verver, Danielle, Grünhagen, Dirk J, van Akkooi, Alexander C J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, Boers-Sonderen, Marye J, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Tije, Albert J Ten, Vreugdenhil, Gerard, Verhoef, Cornelis, and van der Veldt, Astrid A M

Published
2021

116. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease: A Cohort Study

Author

MS Medische Oncologie, Infection & Immunity, Cancer, van der Kooij, Monique K, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van Breeschoten, Jesper, van den Eertwegh, Alfonsus J M, B de Groot, Jan Willem, Haanen, John B A G, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Wouters, Michel W J M, Dekkers, Olaf M, Kapiteijn, Ellen, MS Medische Oncologie, Infection & Immunity, Cancer, van der Kooij, Monique K, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van Breeschoten, Jesper, van den Eertwegh, Alfonsus J M, B de Groot, Jan Willem, Haanen, John B A G, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Wouters, Michel W J M, Dekkers, Olaf M, and Kapiteijn, Ellen

Published
2021

117. Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, de Wreede, Liesbeth C, Hilarius, Doranne H, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers, Marye J, van den Eertwegh, Alfons J M, MS Medische Oncologie, Infection & Immunity, Cancer, Pathologie Pathologen staf, van Breeschoten, Jesper, Wouters, Michel W J M, de Wreede, Liesbeth C, Hilarius, Doranne H, Haanen, John B, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers, Marye J, and van den Eertwegh, Alfons J M

Published
2021

122. The BRAF P.V600E Mutation Status of Melanoma Lung Metastases Cannot Be Discriminated on Computed Tomography by LIDC Criteria nor Radiomics Using Machine Learning

Author

Angus, Lindsay, primary, Starmans, Martijn P. A., additional, Rajicic, Ana, additional, Odink, Arlette E., additional, Jalving, Mathilde, additional, Niessen, Wiro J., additional, Visser, Jacob J., additional, Sleijfer, Stefan, additional, Klein, Stefan, additional, and van der Veldt, Astrid A. M., additional

Published
2021
Full Text
View/download PDF

124. Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy

Author

de With, Mirjam, primary, Hurkmans, Daan P., additional, Oomen-de Hoop, Esther, additional, Lalouti, Ayoub, additional, Bins, Sander, additional, El Bouazzaoui, Samira, additional, van Brakel, Mandy, additional, Debets, Reno, additional, Aerts, Joachim G. J. V., additional, van Schaik, Ron H. N., additional, Mathijssen, Ron H. J., additional, and van der Veldt, Astrid A. M., additional

Published
2021
Full Text
View/download PDF

127. Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy

Author

Blankenstein, Stephanie A, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, van Akkooi, Alexander C J, Blankenstein, Stephanie A, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, and van Akkooi, Alexander C J

Published
2020

128. Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Author

Leeneman, Brenda, Uyl-de Groot, Carin A, Aarts, Maureen J B, van Akkooi, Alexander C J, van den Berkmortel, Franchette W P J, van den Eertwegh, Alfons J M, de Groot, Jan Willem B, Herbschleb, Karin H, van der Hoeven, Jacobus J M, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Haanen, John B A G, Franken, Margreet G, Leeneman, Brenda, Uyl-de Groot, Carin A, Aarts, Maureen J B, van Akkooi, Alexander C J, van den Berkmortel, Franchette W P J, van den Eertwegh, Alfons J M, de Groot, Jan Willem B, Herbschleb, Karin H, van der Hoeven, Jacobus J M, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Haanen, John B A G, and Franken, Margreet G

Published
2020

129. Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Blankenstein, Stephanie A, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, van Akkooi, Alexander C J, MS Medische Oncologie, Infection & Immunity, Cancer, Blankenstein, Stephanie A, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Boers-Sonderen, Marye J, van den Eertwegh, Alfons J M, Franken, Margreet G, de Groot, Jan Willem B, Haanen, John B A G, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, and van Akkooi, Alexander C J

Published
2020

130. Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Leeneman, Brenda, Uyl-de Groot, Carin A, Aarts, Maureen J B, van Akkooi, Alexander C J, van den Berkmortel, Franchette W P J, van den Eertwegh, Alfons J M, de Groot, Jan Willem B, Herbschleb, Karin H, van der Hoeven, Jacobus J M, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Haanen, John B A G, Franken, Margreet G, MS Medische Oncologie, Infection & Immunity, Cancer, Leeneman, Brenda, Uyl-de Groot, Carin A, Aarts, Maureen J B, van Akkooi, Alexander C J, van den Berkmortel, Franchette W P J, van den Eertwegh, Alfons J M, de Groot, Jan Willem B, Herbschleb, Karin H, van der Hoeven, Jacobus J M, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Haanen, John B A G, and Franken, Margreet G

Published
2020

131. The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection

Author

Verver, Daniëlle, Rekkas, A, Garbe, Claus, van Klaveren, David, van Akkooi, Alexander C J, Rutkowski, Piotr, Powell, Barry W E M, Robert, Caroline, Testori, Alessandro, van Leeuwen, Barbara L, van der Veldt, Astrid A M, Keilholz, Ulrich, Stadler, Rudolf, Eggermont, Alexander M M, Verhoef, Cornelis, Leiter, Ulrike, Grünhagen, Dirk J, Verver, Daniëlle, Rekkas, A, Garbe, Claus, van Klaveren, David, van Akkooi, Alexander C J, Rutkowski, Piotr, Powell, Barry W E M, Robert, Caroline, Testori, Alessandro, van Leeuwen, Barbara L, van der Veldt, Astrid A M, Keilholz, Ulrich, Stadler, Rudolf, Eggermont, Alexander M M, Verhoef, Cornelis, Leiter, Ulrike, and Grünhagen, Dirk J

Abstract

PURPOSE: Based on recent advances in the management of patients with sentinel node (SN)-positive melanoma, we aimed to develop prediction models for recurrence, distant metastasis (DM) and overall mortality (OM).METHODS: The derivation cohort consisted of 1080 patients with SN-positive melanoma from nine European Organization for Research and Treatment of Cancer (EORTC) centres. Prognostic factors for recurrence, DM and OM were studied with Cox regression analysis. Significant factors were incorporated in the models. Performance was assessed by discrimination (c-index) and calibration in cross-validation across centres. The models were externally validated using a prospective cohort consisting of 705 German patients with SN-positive: 473 trial participants of the German Dermatologic Cooperative Oncology Group study (DeCOG-SLT) and 232 screened patients. A nomogram was developed for graphical presentation.RESULTS: The final model for recurrence and the calibrated models for DM and OM included ulceration, age, SN tumour burden and Breslow thickness. The models showed reasonable calibration. The c-index for the recurrence, DM and OM model was 0.68, 0.70 and 0.70, respectively, and 0.70, 0.72 and 0.74, respectively, in external validation. The EORTC-DeCOG model identified a robust low-risk group, with all identified low-risk patients (approximately 4% of the entire population) having a 5-year recurrence probability of <25% and an overall 5-year recurrence rate of 13%. A model including information on completion lymph node dissection (CLND) showed only marginal improvement in model performance.CONCLUSIONS: The EORTC-DeCOG nomogram provides an adequate prognostic tool for patients with SN-positive melanoma, without the need for CLND. It showed consistent results across validation. The nomogram could be used for patient counselling and might aid in adjuvant therapy decision-making.

Published
2020

132. Lower risk of severe checkpoint inhibitor toxicity in more advanced disease

Author

MS Medische Oncologie, UMC Utrecht Academie, Cancer, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Infection & Immunity, Verheijden, Rik J, May, Anne M, Blank, Christian U, van der Veldt, Astrid A M, Boers-Sonderen, Marye J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, van der Hoeven, Jacobus J M, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Wouters, Michel W J M, Haanen, John B A G, Kapiteijn, Ellen, Suijkerbuijk, Karijn P M, MS Medische Oncologie, UMC Utrecht Academie, Cancer, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Infection & Immunity, Verheijden, Rik J, May, Anne M, Blank, Christian U, van der Veldt, Astrid A M, Boers-Sonderen, Marye J, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, van den Eertwegh, Alfonsus J M, de Groot, Jan Willem B, van der Hoeven, Jacobus J M, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Ten Tije, Albert J, Vreugdenhil, Gerard, van Zeijl, Michiel C T, Wouters, Michel W J M, Haanen, John B A G, Kapiteijn, Ellen, and Suijkerbuijk, Karijn P M

Published
2020

133. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

Author

MS Medische Oncologie, Infection & Immunity, Cancer, van Zeijl, Michiel C T, Haanen, John B A G, Wouters, Michel W J M, de Wreede, Liesbeth C, Jochems, Anouk, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen W, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van der Hoeven, Koos J M, van den Eertwegh, Alfons J M, MS Medische Oncologie, Infection & Immunity, Cancer, van Zeijl, Michiel C T, Haanen, John B A G, Wouters, Michel W J M, de Wreede, Liesbeth C, Jochems, Anouk, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen W, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, van der Hoeven, Koos J M, and van den Eertwegh, Alfons J M

Published
2020

134. Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response

Author

MS Medische Oncologie, Infection & Immunity, Cancer, van der Kooij, Monique K, Wetzels, Marjolein J A L, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, Dierselhuis, Miranda P, de Groot, Jan Willem B, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Haanen, John B A G, van den Eertwegh, Alfonsus J M, Bastiaannet, Esther, Kapiteijn, Ellen, MS Medische Oncologie, Infection & Immunity, Cancer, van der Kooij, Monique K, Wetzels, Marjolein J A L, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, Dierselhuis, Miranda P, de Groot, Jan Willem B, Hospers, Geke A P, Piersma, Djura, van Rijn, Rozemarijn S, Suijkerbuijk, Karijn P M, Ten Tije, Albert J, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Haanen, John B A G, van den Eertwegh, Alfonsus J M, Bastiaannet, Esther, and Kapiteijn, Ellen

Published
2020

136. Long-Term Survival in Patients With Advanced Melanoma.

Author

van Not, Olivier J., van den Eertwegh, Alfons J. M., Jalving, Hilde, Bloem, Manja, Haanen, John B., van Rijn, Rozemarijn S., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Boers-Sonderen, Marye J., de Groot J. W. B., Jan Willem, Hospers, Geke A. P., Kapiteijn, Ellen, Leeneman, Brenda, D., Piersma, Stevense-den Boer, Marion, van der Veldt, Astrid A. M., Vreugdenhil G., Gerard, Wouters, Michel W. J. M., and Blokx, Willeke A. M.

Published
2024
Full Text
View/download PDF

137. Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer.

Author

Mendelaar, Pauline A. J., Robbrecht, Debbie G. J., Rijnders, Maud, de Wit, Ronald, de Weerd, Vanja, Deger, Teoman, Westgeest, Hans M., Aarts, Maureen J. B., Voortman, Jens, Martens, John W. M., van der Veldt, Astrid A. M., Nakauma-González, José Alberto, Wilting, Saskia M., and Lolkema, Martijn

Abstract

Second-line treatment with immune checkpoint inhibition in patients with metastatic urothelial cancer (mUC) has a low success rate (~ 20%). Circulating tumour-derived DNA (ctDNA) levels may guide patient stratification, provided that an affordable and robust assay is available. Here, we investigate whether the modified fast aneuploidy screening test-sequencing system (mFast-SeqS) may provide such an assay. To this end, mFast-SeqS was performed on cell-free DNA (cfDNA) from 74 patients with mUC prior to treatment with pembrolizumab. Results were associated with corresponding tissue-based profiles, plasma-based variant allele frequencies (VAFs) and clinical response. We found that plasma-derived mFast-SeqS-based aneuploidy scores significantly correlated with those observed in the corresponding tumour tissue as well as with the ctDNA level in the plasma. In multivariate logistic regression analysis, a high aneuploidy score was independently associated with lack of clinical benefit from treatment with pembrolizumab. In conclusion, mFast-SeqS provides a patient-friendly, high-throughput and affordable method to estimate ctDNA level. Following independent validation, this test could be used to stratify mUC patients for response prior to the initiation of treatment with pembrolizumab. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

138. The unfavorable effects of COVID‐19 on Dutch advanced melanoma care.

Author

van Not, Olivier J., van Breeschoten, Jesper, van den Eertwegh, Alfonsus J. M., Hilarius, Doranne L., De Meza, Melissa M., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan Willem B., Hospers, Geke A. P., Ismail, Rawa K., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Stevense‐den Boer, Marion A. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Boers‐Sonderen, Marye J., and Blokx, Willeke A. M.

Subjects
MELANOMA, COVID-19, MEDICAL care, COVID-19 pandemic, ONCOLOGISTS
Abstract

The COVID‐19 pandemic had a severe impact on medical care. Our study aims to investigate the impact of COVID‐19 on advanced melanoma care in the Netherlands. We selected patients diagnosed with irresectable stage IIIc and IV melanoma during the first and second COVID‐19 wave and compared them with patients diagnosed within the same time frame in 2018 and 2019. Patients were divided into three geographical regions. We investigated baseline characteristics, time from diagnosis until start of systemic therapy and postponement of anti‐PD‐1 courses. During both waves, fewer patients were diagnosed compared to the control groups. During the first wave, time between diagnosis and start of treatment was significantly longer in the southern region compared to other regions (33 vs 9 and 15 days, P‐value <.05). Anti‐PD‐1 courses were postponed in 20.0% vs 3.0% of patients in the first wave compared to the control period. Significantly more patients had courses postponed in the south during the first wave compared to other regions (34.8% vs 11.5% vs 22.3%, P‐value <.001). Significantly more patients diagnosed during the second wave had brain metastases and worse performance status compared to the control period. In conclusion, advanced melanoma care in the Netherlands was severely affected by the COVID‐19 pandemic. In the south, the start of systemic treatment for advanced melanoma was more often delayed, and treatment courses were more frequently postponed. During the second wave, patients were diagnosed with poorer patient and tumor characteristics. Longer follow‐up is needed to establish the impact on patient outcomes. What's new? Little is known about the effects of COVID‐19 on advanced melanoma care. In this study, the authors examined several quality indicators of care. They observed a worsening in baseline characteristics, longer time between diagnosis and start of treatment and more postponed anti‐PD‐1 antibody courses with differences between the northern, middle and southern regions. Future studies are necessary to assess the long‐term consequences of our observed changes in advanced melanoma care. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

139. Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy

Author

Blankenstein, Stephanie A., primary, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfons J. M., additional, Franken, Margreet G., additional, de Groot, Jan Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen, additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Suijkerbuijk, Karijn P. M., additional, ten Tije, Albert J., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, and van Akkooi, Alexander C. J., additional

Published
2020
Full Text
View/download PDF

140. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer

Author

Hurkmans, Daan P., primary, Basak, Edwin A., additional, Schepers, Nina, additional, Oomen-De Hoop, Esther, additional, Van der Leest, Cor H., additional, El Bouazzaoui, Samira, additional, Bins, Sander, additional, Koolen, Stijn L. W., additional, Sleijfer, Stefan, additional, Van der Veldt, Astrid A. M., additional, Debets, Reno, additional, Van Schaik, Ron H. N., additional, Aerts, Joachim G. J. V., additional, and Mathijssen, Ron H. J., additional

Published
2020
Full Text
View/download PDF

141. Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Author

Leeneman, Brenda, primary, Uyl-de Groot, Carin A., additional, Aarts, Maureen J. B., additional, van Akkooi, Alexander C. J., additional, van den Berkmortel, Franchette W. P. J., additional, van den Eertwegh, Alfons J. M., additional, de Groot, Jan Willem B., additional, Herbschleb, Karin H., additional, van der Hoeven, Jacobus J. M., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen, additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Suijkerbuijk, Karijn P. M., additional, ten Tije, Albert J., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Haanen, John B. A. G., additional, and Franken, Margreet G., additional

Published
2020
Full Text
View/download PDF

143. Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice.

Author

van Zeijl, Michiel C. T., van den Eertwegh, Alfons J. M., Wouters, Michel W. J. M., de Wreede, Liesbeth C., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan‐Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., ten Tije, Albert J., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, van der Hoeven, Jacobus J. M., and Haanen, John B. A. G.

Subjects
MELANOMA, TREATMENT effectiveness, OVERALL survival, SURVIVAL rate, DISEASE progression
Abstract

There is no consensus on the optimal treatment duration of anti‐PD‐1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti‐PD‐1 discontinuation, the association of treatment duration with progression and anti‐PD‐1 re‐treatment in relapsing patients. Analyses were performed on advanced melanoma patients in the Netherlands who discontinued first‐line anti‐PD‐1 monotherapy in the absence of progressive disease (n = 324). Survival was estimated after anti‐PD‐1 discontinuation and with a Cox model the association of treatment duration with progression was assessed. At the time of anti‐PD‐1 discontinuation, 90 (28%) patients had a complete response (CR), 190 (59%) a partial response (PR) and 44 (14%) stable disease (SD). Median treatment duration for patients with CR, PR and SD was 11.2, 11.5 and 7.2 months, respectively. The 24‐month progression‐free survival and overall survival probabilities for patients with a CR, PR and SD were, respectively, 64% and 88%, 53% and 82%, 31% and 64%. Survival outcomes of patients with a PR and CR were similar when anti‐PD‐1 discontinuation was not due to adverse events. Having a PR at anti‐PD‐1 discontinuation and longer time to first response were associated with progression [hazard ratio (HR) = 1.81 (95% confidence interval, CI = 1.11‐2.97) and HR = 1.10 (95% CI = 1.02‐1.19; per month increase)]. In 17 of the 27 anti‐PD‐1 re‐treated patients (63%), a response was observed. Advanced melanoma patients can have durable remissions after (elective) anti‐PD‐1 discontinuation. What's new? Reasons for discontinuing treatment with the anti‐PD‐1 antibodies nivolumab and pembrolizumab can vary significantly among melanoma patients. Moreover, the optimal treatment duration for these drugs remains unclear. In this observational study on anti‐PD‐1 discontinuation, most patients with advanced melanoma who had complete or partial response at anti‐PD‐1 discontinuation experienced ongoing response, with potential survival benefits. Shorter time to first response of anti‐PD‐1 monotherapy and partial response at discontinuation were associated with later progression of disease. Elective discontinuation, by contrast, was linked to a reduced likelihood of subsequent progression. Anti‐PD‐1 retreatment exhibited clinical activity against melanoma, warranting further investigation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

145. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

Author

Menzer, Christian, Menzies, Alexander M, Carlino, Matteo S, Reijers, Irene, Groen, Emma J, Eigentler, Thomas, de Groot, Jan Willem B, van der Veldt, Astrid A M, Johnson, Douglas B, Meiss, Frank, Schlaak, Max, Schilling, Bastian, Westgeest, Hans M, Gutzmer, Ralf, Pföhler, Claudia, Meier, Friedegund, Zimmer, Lisa, Suijkerbuijk, Karijn P M, Haalck, Thomas, Thoms, Kai-Martin, Leichsenring, Jonas, Menzer, Alexander, Kopp-Schneider, Annette, Long, Georgina V, Kefford, Richard, Enk, Alexander, Blank, Christian U, Hassel, Jessica C, Menzer, Christian, Menzies, Alexander M, Carlino, Matteo S, Reijers, Irene, Groen, Emma J, Eigentler, Thomas, de Groot, Jan Willem B, van der Veldt, Astrid A M, Johnson, Douglas B, Meiss, Frank, Schlaak, Max, Schilling, Bastian, Westgeest, Hans M, Gutzmer, Ralf, Pföhler, Claudia, Meier, Friedegund, Zimmer, Lisa, Suijkerbuijk, Karijn P M, Haalck, Thomas, Thoms, Kai-Martin, Leichsenring, Jonas, Menzer, Alexander, Kopp-Schneider, Annette, Long, Georgina V, Kefford, Richard, Enk, Alexander, Blank, Christian U, and Hassel, Jessica C

Published
2019

146. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Author

Verhoeff, Sarah R, van Es, Suzanne C, Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G, Oosting, Sjoukje F, Aarntzen, Erik H, Brouwers, Adrienne H, Kwee, Thomas C, Heskamp, Sandra, Hoekstra, Otto S, Verheul, Henk, van der Veldt, Astrid A M, de Vries, Elisabeth G E, Boerman, Otto C, van der Graaf, Winette T A, Oyen, Wim J G, van Herpen, Carla M L, Verhoeff, Sarah R, van Es, Suzanne C, Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G, Oosting, Sjoukje F, Aarntzen, Erik H, Brouwers, Adrienne H, Kwee, Thomas C, Heskamp, Sandra, Hoekstra, Otto S, Verheul, Henk, van der Veldt, Astrid A M, de Vries, Elisabeth G E, Boerman, Otto C, van der Graaf, Winette T A, Oyen, Wim J G, and van Herpen, Carla M L

Published
2019

147. Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

Author

MS Medische Oncologie, Cancer, Menzer, Christian, Menzies, Alexander M, Carlino, Matteo S, Reijers, Irene, Groen, Emma J, Eigentler, Thomas, de Groot, Jan Willem B, van der Veldt, Astrid A M, Johnson, Douglas B, Meiss, Frank, Schlaak, Max, Schilling, Bastian, Westgeest, Hans M, Gutzmer, Ralf, Pföhler, Claudia, Meier, Friedegund, Zimmer, Lisa, Suijkerbuijk, Karijn P M, Haalck, Thomas, Thoms, Kai-Martin, Leichsenring, Jonas, Menzer, Alexander, Kopp-Schneider, Annette, Long, Georgina V, Kefford, Richard, Enk, Alexander, Blank, Christian U, Hassel, Jessica C, MS Medische Oncologie, Cancer, Menzer, Christian, Menzies, Alexander M, Carlino, Matteo S, Reijers, Irene, Groen, Emma J, Eigentler, Thomas, de Groot, Jan Willem B, van der Veldt, Astrid A M, Johnson, Douglas B, Meiss, Frank, Schlaak, Max, Schilling, Bastian, Westgeest, Hans M, Gutzmer, Ralf, Pföhler, Claudia, Meier, Friedegund, Zimmer, Lisa, Suijkerbuijk, Karijn P M, Haalck, Thomas, Thoms, Kai-Martin, Leichsenring, Jonas, Menzer, Alexander, Kopp-Schneider, Annette, Long, Georgina V, Kefford, Richard, Enk, Alexander, Blank, Christian U, and Hassel, Jessica C

Published
2019

148. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Author

Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, Arts-assistenten Radiologie, Verhoeff, Sarah R, van Es, Suzanne C, Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G, Oosting, Sjoukje F, Aarntzen, Erik H, Brouwers, Adrienne H, Kwee, Thomas C, Heskamp, Sandra, Hoekstra, Otto S, Verheul, Henk, van der Veldt, Astrid A M, de Vries, Elisabeth G E, Boerman, Otto C, van der Graaf, Winette T A, Oyen, Wim J G, van Herpen, Carla M L, Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, Arts-assistenten Radiologie, Verhoeff, Sarah R, van Es, Suzanne C, Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G, Oosting, Sjoukje F, Aarntzen, Erik H, Brouwers, Adrienne H, Kwee, Thomas C, Heskamp, Sandra, Hoekstra, Otto S, Verheul, Henk, van der Veldt, Astrid A M, de Vries, Elisabeth G E, Boerman, Otto C, van der Graaf, Winette T A, Oyen, Wim J G, and van Herpen, Carla M L

Published
2019

149. Recente behandelresultaten van uitgezaaid melanoom : Gegevens uit de Dutch Melanoma Treatment Registry

Author

van Zeijl, Michiel C. T., van den Eertwegh, Alfons J. M., Wouters, Michel W. J. M., Jochems, Anouk, Schouwenburg, Maartje G., Haanen, John B. A. G., Aarts, Maureen J., van den Berkmortel, Franchette W. P. J., de Groot, Jan Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Koornstra, Rutger H., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., ten Tije, Albert J., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, van der Hoeven, Koos J. M., Guided Treatment in Optimal Selected Cancer Patients, Medical oncology, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, and VU University medical center

Subjects
Adult, Male, Medicine(all), Antineoplastic Agents/therapeutic use, Registries/statistics & numerical data, Brain Neoplasms/drug therapy, Netherlands/epidemiology, Kaplan-Meier Estimate, Middle Aged, Treatment Outcome, Skin Neoplasms/drug therapy, Humans, Female, Melanoma/drug therapy, Prospective Studies, Aged, Neoplasm Staging
Abstract

Doel Evaluatie van de behandelstrategieën en overleving van patiënten met irresectabel melanoom stadium IIIc of IV sinds de introductie van nieuwe geneesmiddelen in 2012 in Nederland. Opzet Prospectieve cohortstudie. Methode Wij analyseerden gegevens uit de Dutch Melanoma Treatment Registry (DMTR) van patiënten die in de periode 1 juli 2012-31 december 2015 waren gediagnosticeerd met irresectabel melanoom stadium IIIc of IV. We schatten de overlevingsduur met de Kaplan-Meier-methode. De relatie tussen jaar van diagnose en overleving werd geschat met Cox-regressieanalyse, gecorrigeerd voor leeftijd, ‘WHO performance status’, lactaatdehydrogenasewaarde, tumorstadium, hersenmetastasen en afstandsmetastasen. Resultaten Van de geregistreerde 2768 patiënten kreeg ongeveer driekwart systemische therapie; deze behandeling was elk jaar aan verandering onderhevig. De mediane overlevingsduur was 10,7 maanden (95%-BI: 9,6-13,2) in 2012 en 13,8 maanden (95%-BI: 11,8-15,6) in 2015; de mediane overlevingsduur voor systemisch behandelde patiënten was 17,1 maanden in 2015. De 2- jaarsoverleving nam in deze periode toe van 23 tot 40%. Patiënten gediagnosticeerd in 2015 hadden een betere overleving dan patiënten uit 2014 (hazardratio (HR): 0,82; 95%-BI: 0,73-0,93). Dit effect gold ook voor patiënten die werden behandeld met systemische therapie (HR: 0,79; 95%-BI: 0,69-0,91). Conclusie De snelle beschikbaarheid van nieuwe geneesmiddelen, die door de toenmalige minister van VWS en de beroepsgroep is geïnitieerd, heeft de behandeling van patiënten met irresectabel melanoom stadium IIIc of IV ingrijpend veranderd. De gegevens uit de DMTR duiden op een veilig gebruik van deze nieuwe geneesmiddelen in de dagelijkse praktijk en een verbetering van de overleving van patiënten met gevorderd melanoom in de afgelopen jaren.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results